Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

NeoTILs: A Phase II Study of Biomarker-Guided De-escalation Using Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early-Stage Triple Negative Breast Cancer (TNBC) Patients With High Tumor-Infiltrating Lymphocytes (TILs)

NCT07743190 is registered in ClinicalTrials.gov with Medical University of South Carolina as lead sponsor.

NCT NCT07743190
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07743190 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
NeoTILs: A Phase II Study of Biomarker-Guided De-escalation Using Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early-Stage Triple Negative Breast Cancer (TNBC) Patients With High Tumor-Infiltrating Lymphocytes (TILs)
Lead sponsor
Medical University of South Carolina
Phase
Phase 2
Overall status
Recruiting
Start date
October 1, 2026
Completion date
March 1, 2030
Enrollment
55 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

elevated tumor-infiltrating lymphocytes, triple negative breast cancer (tnbc)